2023 Volume 40 Issue 5 Pages 645-652
This single-center, exploratory, retrospective observational study explores the efficacy and safety of fosravuconazole L-lysine ethanolate (NAILIN® capsule, “F-RVCZ”) in patients with onychomycosis who were switched from a topical antifungal drug (“topical drug”). The average duration of administration of the topical drug was 24.3 months. All patients were switched to F-RVCZ due to insufficient effects. The average involvement ratio at the start of treatment was 7.8, and many patients had severe disease. However, the clinical cure rate at 48 weeks was 62.5%; therefore, F-RVCZ had a high efficacy when switching from topical drugs. Adverse reactions were observed in 13 patients (25.0%), three of which led to discontinuation. All adverse reactions were known symptoms and were resolved after the discontinuation of F-RVCZ. F-RVCZ, which has relatively few interactions and safety concerns, has a high therapeutic effect after a short-term administration of 12 weeks even in patients who report insufficient efficacy with the use of topical drugs.
